How do I talk about SSRIs when the internet is having another fight?

Stay with the person in the chair. Why they started, what changed, what still hurts, what you are doing this month. Do not spend the assessment litigating a newspaper.

There is another SSRI round on the internet this week. There always is. This time it is an essay, a pile of anecdotes about sexual dysfunction and youth black-box warnings, and the usual claim that everyone gets the same pill for every complaint. Some of that is a real clinical problem I under-ask. Some of it is a sermon. The chart only has room for this patient.

Their worry, in their words

“I read that these drugs make you numb and I think that’s why I don’t care about my job.” That sentence is the visit. “Patient with questions about medication” is how you lose it.

I answer the part that is about them. Duration. Dose. Whether they ever had a window off it. Whether the numbness started at week two or year five. Whether they can still cry at movies. I do not assign them a camp.

If they want off, we taper. I write the taper like a covering clinician has to follow it. I also write what happened last time they stopped in three days and did not sleep. That is not scare language. That is their history.

What I had gotten lazy about

Sexual function. I still skip it when I am late. Then I act surprised when they quit in silence. Ask. Write the answer. If they have it, name the options you offered (dose, wait, add bupropion, switch, stop). If they decline to discuss it, write that. Do not invent “no side effects.”

Missed doses and discontinuation. Paroxetine is not fluoxetine. If they feel electric zaps on Thursday after missing Wednesday, that belongs in the note. People online call that proof of harm. Sometimes it is withdrawal. The plan is a slower taper, not a speech.

Why this drug, still. “MDD, continue” is the sentence the essay writers are aiming at, and they are not always wrong. “Panic attacks weekly in March, none this month, still avoiding the subway, holding 20 mg until ERP starts” is a reason.

What I will not put in the chart

A paragraph about serotonin theory. A citation war. “Patient has been reading MAHA Twitter.” If the source matters, name the source they named. If it doesn’t, skip it.

A promise that SSRIs are harmless in young people. The boxed warning exists. If I start one in an 18-year-old, I write the monitoring I actually planned, and who will see them next week. If I refuse to start one because the presentation is something else, I write that something else.

A conversion to ketamine, psilocybin, or “anything but an SSRI” because the internet is loud this week. Those are separate conversations with their own facts. See ketamine and psychedelics.

Questions I get

Do I document that I discussed the black-box warning every time I refill? For a stable adult on year four, I do not paste the warning each visit. For a start, a dose jump, or an adolescent, I do. Use judgment and be consistent inside a clinic.

What if they are doing well and want to stop anyway? That is a legitimate visit. Write the goal, the taper, and what would make you restart. Do not punish them in the wording.

Can an AI draft handle this? It will smooth their anger into “medication concerns.” Put the angry sentence back before you sign.